Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.